A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
CAMBRIA-2
NCT05952557
 Recruiting
|
CISSS DE CHAUDIERE-APPALACHES
HOTEL-DIEU DE LEVIS
|
Breast |
Dr. Vincent Barrette
Pierre Bédard
418-835-7121
|
Randomized Trial of Hypofractionated LocoRegional Radiotherapy in Breast Cancer and Lymphedema
RHEAL
NCT04228991
Recruiting
|
CISSS DE CHAUDIERE-APPALACHES
HOTEL-DIEU DE LEVIS
|
Breast |
Dr. Anne Dagnault
Pierre Bédard
418-835-7121
|
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
TROPION-Breast04
NCT06112379
Recruiting
|
CISSS DE CHAUDIERE-APPALACHES
HOTEL-DIEU DE LEVIS
|
Breast |
Dr. Vincent Barrette
Pierre Bédard
418-835-7121
|
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
CRC10 (NRG-GI008)
NCT05174169
Recruiting
|
CISSS DE CHAUDIERE-APPALACHES
HOTEL-DIEU DE LEVIS
|
Colon and Rectum |
Dr. Vincent Barrette
Pierre Bédard
418-835-7121
|
A Comprehensive and Observational Myeloproliferative Neoplasms (MPN) Registry in the Province of Quebec
Registre des NMP (CINC424BCA04T)
Recruiting
|
CISSS DE CHAUDIERE-APPALACHES
HOTEL-DIEU DE LEVIS
|
MPN: Vaquez, Essential Thrombocytemia, Myeloid Metaplasia |
Dr. Danièle Marceau
Pierre Bédard
418-835-7121
|
A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).
eVOLVE-Lung02
NCT05984277
Recruiting
|
CISSS DE CHAUDIERE-APPALACHES
HOTEL-DIEU DE LEVIS
|
Non Small Cells - Lung |
Dr. Marie-Ève Boucher
Pierre Bédard
418-835-7121
|
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer
ARASTEP
NCT05794906
Recruiting
|
CISSS DE CHAUDIERE-APPALACHES
HOTEL-DIEU DE LEVIS
|
Prostate |
Dr. Matthieu Gratton
Estel Duquet Deblois
418-835-7121 poste 11790
|
Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters: a Randomized Controlled Trial
TRIM-Line 3698
NCT05029063
Recruiting
|
CISSS DE CHAUDIERE-APPALACHES
HOTEL-DIEU DE LEVIS
|
Symptoms Management |
Dr. Frédéric Larose
Pierre Bédard
418-835-7121
|
Groupe d'étude en oncologie du Québec